SOURCE: The Bedford Report

The Bedford Report

July 28, 2011 08:16 ET

Positive FDA Trends Bode Well for Ariad and Human Genome Sciences

The Bedford Report Provides Equity Research on Ariad Pharmaceuticals & Human Genome Sciences

NEW YORK, NY--(Marketwire - Jul 28, 2011) - There is plenty of optimism surrounding the biotechnology industry as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) and Human Genome Sciences, Inc. (NASDAQ: HGSI). Access to the full company reports can be found at:

www.bedfordreport.com/ARIA

www.bedfordreport.com/HGSI

Citing agency officials, The Wall Street Journal reported this month that the Food and Drug Administration (FDA) has approved 20 new drugs so far this year -- just one short of the total for all of 2010. Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and hurting the pharmaceutical and biotech industry.

Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.

The Bedford Report releases stock research on theBiotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Human Genome Sciences -- whose lupus drug Benlysta was cleared for marketing by the FDA earlier this year -- recently reported a loss of $80.7 million, or 42 cents a share, for the three months ended June 30. That compares with a net loss of $56.9 million, or 30 cents a share, in the prior-year quarter. The company's management says it is making good progress with the US launch of Benlysta, adding that it received approval earlier this month to market the drug in Europe and Canada.

Ariad Pharmaceuticals is set to report second quarter earnings next Tuesday. Recently the company, in partnership with Merck, announced positive results from a Phase 3 study of their sarcoma drug, ridaforolimus. Studies showed a 28 percent reduction in the risk of progression or death in those treated with ridaforolimus compared to placebo. Based on the drug's performance in the trial, Merck plans to file for approval in the US and Europe this year.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information